Alto Neuroscience (ANRO) said late Tuesday a phase 2b study of ALTO-100 in patients with major depressive disorder failed to meet its primary endpoint compared with placebo.
"Treatment with ALTO-100 did not demonstrate improvement in depressive symptoms compared to placebo in patients with a memory-based cognitive biomarker," Alto Neuroscience said.
ALTO-100 is also being evaluated as an adjunctive treatment in a phase 2b study for bipolar depression, the company said.
Alto expects its current cash position to fund planned operations into 2027 and through multiple upcoming clinical readouts.
Shares of the company plunged 60% in after-hours activity on Tuesday.
Price: 5.82, Change: -8.71, Percent Change: -59.94
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。